Are you Dr. Abdelrahim?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 58 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
6445 Main St
# OPC24
Houston, TX 77030Phone+1 713-441-9948Fax+1 713-793-1642
Summary
- Dr. Maen Abdelrahim, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas and North Carolina. He is affiliated with Houston Methodist Hospital, Houston Methodist Sugar Land Hospital, and Houston Methodist West Hospital.
Education & Training
Baylor College of MedicineResidency, Internal Medicine, 2012 - 2015
Texas A&M; Health Science Center College of MedicineClass of 2012
Certifications & Licensure
TX State Medical License 2014 - 2025
NC State Medical License 2015 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer Start of enrollment: 2021 Feb 10
Publications & Presentations
PubMed
- 97 citationsA multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplantNaoka Murakami, Patrick M. Mulvaney, Melissa J. Danesh, Ala Abudayyeh, Adi Diab
Kidney International. 2021-07-01 - 20 citationsUtilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.Maen Abdelrahim, Abdullah Esmail, Ashish Saharia, Ala Abudayyeh, Noha Abdel-Wahab
Cancers. 2022-03-30 - 22 citationsImmunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report.Maen Abdelrahim, Abdullah Esmail, Godsfavour Umoru, Kiersten Westhart, Ala Abudayyeh
Current Oncology. 2022-06-15
Press Mentions
Surgical Options for Cholangiocarcinoma Enhance SurvivalJuly 19th, 2024- Study Finds Daily Aspirin Use Improves Colorectal Cancer OutcomesJuly 19th, 2024
New Recommendation to Start Colorectal Cancer Screenings at Age 45: What to KnowFebruary 4th, 2020- Join now to see all
